CompletedEUCTR 2010-023623-26

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depressio...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesBipolarity

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Bulgaria · Finland and 4 more locations
Study phase: Phase 3

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 370
Sponsor: Cephalon, Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Bulgaria, Finland, Germany, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2010-023623-26
Official title: Show the full official title
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depressio...

Looking for a study you can join?

Explore recruiting studies

Get this study by email

Recruitment & locations

Completed

Bulgaria · Finland · Germany

3 more locations

Hungary
Italy
Poland

Registry details

Historical country statuses

Bulgaria — Completed
Germany — Completed
Finland — Completed
Hungary — Completed
Italy — Completed
Poland — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Cephalon, Inc.

Want to explore more studies?

Explore studies